RT Journal Article
T1 Genetic LGALS1 Variants Are Associated with Heterogeneity in Galectin-1 Serum Levels in Patients with Early Arthritis
A1 Triguero-Martínez, Ana
A1 Roy-Vallejo, Emilia
A1 Montes, Nuria
A1 Fuente, Hortensia de la
A1 Ortiz, Ana María
A1 Castañeda, Santos
A1 González-Álvaro, Isidoro
A1 Lamana Domínguez, Amalia
AB Galectin 1 (Gal1) exerts immunomodulatory effects leading to therapeutic effects in autoimmune animal models. Patients with rheumatoid arthritis have been reported to show higher Gal1 serum levels than the healthy population. Our study aimed to find genetic variants on the Gal1 gene (LGALS1) modulating its expression and/or clinical features in patients with early arthritis (EA). LGALS1 was sequenced in 53 EA patients to characterize all genetic variants. Then, we genotyped rs9622682, rs929039, and rs4820293, which covered the main genetic variation in LGALS1, in 532 EA patients. Gal1 and IL-6 serum levels were measured by ELISA and Gal1 also by western blot (WB) in lymphocytes from patients with specific genotypes. Once disease activity improved with treatment, patients with at least one copy of the minor allele in rs9622682 and rs929039 or those with GG  genotype in rs4820293 showed significantly higher Gal1 serum levels (p < 0.05). These genotypic combinations were also associated with higher Gal1 expression in lymphocytes by WB and lower IL-6 serum levels in EA patients. In summary, our study suggests that genetic variants studied inLGALS1 can explain heterogeneity in Gal1 serum levels showing that patients with higher Gal1 levels have lower serum IL-6 levels.
PB MDPI
SN 1422-0067
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/94197
UL https://hdl.handle.net/20.500.14352/94197
LA eng
NO Triguero-Martínez, A.; Roy-Vallejo, E.; Montes, N.; de la Fuente, H.; Ortiz, A.M.; Castañeda, S.; González-Álvaro, I.; Lamana, A. Genetic LGALS1 Variants Are Associated with Heterogeneity in Galectin-1 Serum Levels in Patients with Early Arthritis. Int. J. Mol. Sci. 2022, 23, 7181. https://doi.org/10.3390/ijms23137181
NO This research was funded by grants RD21/0002/0027 and PI21/00526 to I.G.-Á, PI21/01583 to H.d.l.F. and PI21/01474 to S.C. from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and co-funded by European Regional Development Fund (ERDF) “A way to make Europe”. The work of E.R.-V. is currently funded by a grant Rio-Hortega CM19/00149 from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and co-funded by European Regional Development Fund (ERDF) “A way to make Europe”.
NO Ministerio de Economía y Competitividad (España)
NO European Commission
DS Docta Complutense
RD 18 dic 2025